Through innovative devices and diagnostics, we deliver value to patients, healthcare professionals, and healthcare systems.
In our endeavor to build an Asia-based precision medicine platform, we seek out strategic equity investments in medical technology companies that can help us achieve this goal.
Our key medical technology investments include:
- Biolidics Limited (Biolidics) is listed on the Singapore Stock Exchange (Catalist Board: 8YY), an associate company which owns one of the world’s most advanced fully automated circulating tumor cell enrichment technology and is developing complete liquid biopsies solutions for clinical use.
- Clearbridge BioPhotonics FPM Inc (CBBP), a subsidiary company, developed the world’s first working prototype FPM system for live cell imaging studies in drug discovery and is developing higher throughout imaging systems in computational microscopy to radically change optical microscopy.
- Singapore Institute of Advance Medicine Holdings (SIAMH) is building an advanced proton therapy centre in Singapore.